247 related articles for article (PubMed ID: 23859576)
1. Mobilizing pharmacogenomic analyses during clinical trials in drug development.
Bienfait KL; Shaw PM; Murthy G; Warner AW
Pharmacogenomics; 2013 Jul; 14(10):1227-35. PubMed ID: 23859576
[TBL] [Abstract][Full Text] [Related]
2. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
Roses AD
Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
[TBL] [Abstract][Full Text] [Related]
3. Economic advantage of pharmacogenomics - clinical trials with genetic information.
Ohashi W; Mizushima H; Tanaka H
Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics in drug development.
McCarthy AD; Kennedy JL; Middleton LT
Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1579-88. PubMed ID: 16096107
[TBL] [Abstract][Full Text] [Related]
5. Current pharmacogenomic approaches to clinical drug development.
Murphy MP
Pharmacogenomics; 2000 May; 1(2):115-23. PubMed ID: 11256585
[TBL] [Abstract][Full Text] [Related]
6. Collaborative Counseling Considerations for Pharmacogenomic Tests.
Zierhut HA; Campbell CA; Mitchell AG; Lemke AA; Mills R; Bishop JR
Pharmacotherapy; 2017 Sep; 37(9):990-999. PubMed ID: 28672074
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic biomarkers for predicting drug response.
Bank PC; Swen JJ; Guchelaar HJ
Expert Rev Mol Diagn; 2014 Jul; 14(6):723-35. PubMed ID: 24857685
[TBL] [Abstract][Full Text] [Related]
8. Implications of pharmacogenomics for drug development.
Kirk RJ; Hung JL; Horner SR; Perez JT
Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
[TBL] [Abstract][Full Text] [Related]
9. Company profile: PGXIS Ltd.
McCarthy A
Pharmacogenomics; 2011 Sep; 12(9):1253-6. PubMed ID: 21919604
[TBL] [Abstract][Full Text] [Related]
10. Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs.
Stingl Kirchheiner JC; Brockmöller J
Clin Pharmacol Ther; 2011 Feb; 89(2):198-209. PubMed ID: 21209614
[TBL] [Abstract][Full Text] [Related]
11. The impact of pharmacogenomics research on drug development.
Liou SY; Stringer F; Hirayama M
Drug Metab Pharmacokinet; 2012; 27(1):2-8. PubMed ID: 22214937
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of medications given via nonconventional administration routes: a scoping review.
Socco S; Wake DT; Lee JC; Dunnenberger HM
Pharmacogenomics; 2022 Nov; 23(17):933-948. PubMed ID: 36326000
[TBL] [Abstract][Full Text] [Related]
13. Limitations of pharmacogenomic predictor discovery in Phase II clinical trials.
Pusztai L
Pharmacogenomics; 2007 Oct; 8(10):1443-8. PubMed ID: 17979517
[TBL] [Abstract][Full Text] [Related]
14. Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG).
Bienfait K; Chhibber A; Marshall JC; Armstrong M; Cox C; Shaw PM; Paulding C
Hum Genet; 2022 Jun; 141(6):1165-1173. PubMed ID: 34081195
[TBL] [Abstract][Full Text] [Related]
15. Current Japanese regulatory situations of pharmacogenomics in drug administration.
Ishiguro A; Toyoshima S; Uyama Y
Expert Rev Clin Pharmacol; 2008 Jul; 1(4):505-14. PubMed ID: 24410553
[TBL] [Abstract][Full Text] [Related]
16. Novel technology and the development of pharmacogenetics within the pharmaceutical industry.
Gibson N; Jawaid A; March R
Pharmacogenomics; 2005 Jun; 6(4):339-56. PubMed ID: 16004553
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice.
Shahabi P; Dubé MP
Int J Cardiol; 2015 Apr; 184():772-795. PubMed ID: 25838112
[TBL] [Abstract][Full Text] [Related]
18. Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies.
Nagy M; Attya M; Patrinos GP
Pharmacogenomics; 2020 Nov; 21(17):1247-1264. PubMed ID: 33124490
[TBL] [Abstract][Full Text] [Related]
19. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
Otsubo Y
Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives.
Prasad K; Breckenridge A
Drug Discov Today; 2011 Oct; 16(19-20):867-72. PubMed ID: 21920454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
